The DOI matches its Crossref record.
Ketoconazole for Early Treatment of Acute Lung Injury and Acute Respiratory Distress Syndrome: A Randomized Controlled Trial
Abstract
CONTEXT: Three clinical studies have suggested that ketoconazole, a synthetic imidazole with anti-inflammatory activity, may prevent the development of acute respiratory distress syndrome (ARDS) in critically ill patients. However, the use of ketoconazole as treatment for acute lung injury (ALI) and ARDS has not been previously studied. OBJECTIVE: To test the efficacy of ketoconazole in reducing mortality and morbidity in patients with ALI or ARDS. DESIGN: Randomized, double-blind, placebo-controlled trial conducted from March 1996 to January 1997. SETTING: Twenty-four hospitals associated with 10 network centers in the United States, constituting the ARDS Network. PATIENTS: A total of 234 patients with ALI or ARDS. INTERVENTION: Patients were randomly assigned to receive ketoconazole, 400 mg/d (n = 117), or placebo (n = 117), initiated within 36 hours of fulfilling study entry criteria and given enterally for up to 21 days. MAIN OUTCOME MEASURES: Primary outcome measures were the proportion of patients alive with unassisted breathing at hospital discharge and the number of days of unassisted breathing (ventilator-free days) during 28 days of follow-up. Secondary outcome measures included the proportion of patients achieving unassisted breathing for 48 hours or more, the number of organ failure-free days, and changes in plasma interleukin 6 (IL-6) and urinary thromboxane A2 metabolites (thromboxane B2 [TXB2] and 11-dehydro-TXB2). RESULTS: In-hospital mortality (SE) was 34.1% (4.3%) for the placebo group and 35.2% (4.3%) for the ketoconazole group (P=.85). The median number of ventilator-free days within 28 days of randomization was 9 in the placebo group and 10 in the ketoconazole group (P=.89). There were no statistically significant differences in the number of organ failure-free days, pulmonary physiology, or adverse events between treatment groups. The median serum ketoconazole level was 1.25 microg/mL and serum levels greater than 0.5 microg/mL were detected in 96% of patients assayed. Plasma IL-6, urinary TXB2, and 11-dehydro-TXB2 levels were unaffected by ketoconazole. CONCLUSIONS: In these patients with ALI or ARDS, ketoconazole was safe and bioavailable but did not reduce mortality or duration of mechanical ventilation or improve lung function. These data do not support the use of ketoconazole for the early treatment of ALI or ARDS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
The Acute Respiratory Distress Syndrome
Ware, L. B., & Matthay, M. A. (2000) · New England Journal of Medicine · doi:10.1056/nejm200005043421806 · Cited by 4,666
Calfee, C. S., Delucchi, K., Parsons, P. E., Thompson, B. T., Ware, L. B., & Matthay, M. A. (2014) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(14)70097-9 · Cited by 1,544
Acute lung injury and the acute respiratory distress syndrome: a clinical review
Wheeler, A. P., & Bernard, G. R. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60604-7 · Cited by 904
Acute Lung Injury: Epidemiology, Pathogenesis, and Treatment
Johnson, E. R., & Matthay, M. A. (2010) · Journal of Aerosol Medicine and Pulmonary Drug Delivery · doi:10.1089/jamp.2009.0775 · Cited by 783
Has Mortality from Acute Respiratory Distress Syndrome Decreased over Time?: A Systematic Review
Phua, J., Badia, J. R., Adhikari, N. K. J., Friedrich, J. O., Fowler, R. A., Singh, J. M., Scales, D. C., Stather, D. R., Li, A., Jones, A., et al. (2009) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200805-722oc · Cited by 727
Metadata
- Authors
- The ARDS Network Authors for the ARDS Network
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2000-04-19
- Volume
- 283
- Issue
- 15
- Pages
- 1995
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W4248053214
- Cited by
- 264
- References
- 0
- FWCI
- 9.44
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Ketoconazole for Early Treatment of Acute Lung Injury and Acute Respiratory Distress Syndrome: A Randomized Controlled Trial. https://app.cochat.ai/papers/10.1001/jama.283.15.1995
- The paper
- The ARDS Network Authors for the ARDS Network. (2000). Ketoconazole for Early Treatment of Acute Lung Injury and Acute Respiratory Distress Syndrome: A Randomized Controlled Trial. JAMA. https://doi.org/10.1001/jama.283.15.1995
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.